Search details
1.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35313048
2.
New Frontiers in the Medical Therapy of Hepatocellular Carcinoma.
Chemotherapy
; 67(3): 164-172, 2022.
Article
in English
| MEDLINE | ID: mdl-34999584
5.
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study.
Clin Cancer Res
; 2024 Apr 05.
Article
in English
| MEDLINE | ID: mdl-38578610
6.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
JHEP Rep
; 6(2): 100982, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38274490
7.
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials.
JHEP Rep
; 5(5): 100702, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37025943
8.
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 10: 1955-1971, 2023.
Article
in English
| MEDLINE | ID: mdl-37941812
9.
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.
Cancers (Basel)
; 15(20)2023 Oct 19.
Article
in English
| MEDLINE | ID: mdl-37894419
10.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hepatol Int
; 17(4): 904-914, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37005953
11.
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Oncol
; 9(10): 1423-1431, 2023 Oct 01.
Article
in English
| MEDLINE | ID: mdl-37615958
12.
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
Expert Opin Investig Drugs
; 31(7): 681-691, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35507361
13.
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma.
Expert Rev Mol Diagn
; 22(3): 253-264, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35236211
14.
Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.
J Bone Oncol
; 34: 100422, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35309238
15.
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Cancers (Basel)
; 14(23)2022 Nov 26.
Article
in English
| MEDLINE | ID: mdl-36497316
16.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Eur J Cancer
; 175: 204-213, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36148739
17.
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 20(6): 558-567, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36155169
18.
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 20(5): e440-e452, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35778337
19.
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.
Cancers (Basel)
; 14(1)2021 Dec 31.
Article
in English
| MEDLINE | ID: mdl-35008350
20.
Prognostic and predictive factors in pancreatic cancer.
Oncotarget
; 11(10): 924-941, 2020 Mar 10.
Article
in English
| MEDLINE | ID: mdl-32206189